Selective deep brain stimulation in the substantia nigra reduces myoclonus in progressive myoclonic epilepsy: a novel observation and short review of the literature

被引:22
作者
di Giacopo, Andrea [1 ,2 ]
Baumann, Christian R. [1 ,2 ]
Kurthen, Martin [3 ]
Capecchi, Francesco [1 ,2 ]
Sueruecue, Oguzkan [4 ]
Imbach, Lukas L. [1 ,2 ]
机构
[1] Univ Hosp, Dept Neurol, Zurich, Switzerland
[2] Univ Zurich, Zurich, Switzerland
[3] Swiss Epilepsy Ctr, Zurich, Switzerland
[4] Univ Hosp Zurich, Dept Neurosurg, Zurich, Switzerland
关键词
Progressive epilepsy myoclonus; DBS; STN; SNr transitional zone; drug-resistant epilepsy; LEVETIRACETAM;
D O I
10.1684/epd.2019.1072
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report the case of a patient suffering from pharmacotherapy-resistant bilateral progressive myoclonic epilepsy (PME) showing a beneficial response upon selective deep brain stimulation (DBS) of the substantia nigra pars reticulata. As an individual experimental therapeutic approach, we implanted DBS electrodes in the transitional zone between the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr). Electrode placement allowed for a selective stimulation of either the STN, SNr, or both targets. Postoperatively, we observed a moderate subjective and objective improvement in positive and negative myoclonus by high-frequency DBS of the STN/SNr transitional zone. However, a systematic exploration of different stimulation settings revealed that monopolar stimulation of the substantia nigra alone was more effective than high-frequency monopolar DBS of either the motor STN (monopolar) or stimulation of both targets (STN/SNr). This observation confirms earlier findings showing that patients with PME benefit from high-frequency DBS. However, in contrast to previous reports stimulating the STN/SNr transitional zone, our patient showed the most significant effect upon selective stimulation of the SNr. We propose that in patients undergoing DBS for myoclonus, at least one electrode contact should be placed in the SNr allowing for selective monopolar stimulation of this target.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 19 条
[1]   Add-on therapy with topiramate in progressive myoclonic epilepsy [J].
Aykutlu, E ;
Baykan, B ;
Gürses, C ;
Bebek, N ;
Büyükbabani, N ;
Gökyigit, A .
EPILEPSY & BEHAVIOR, 2005, 6 (02) :260-263
[2]  
Benabid AL, 2002, NEUROSURGERY, V50, P1385
[3]  
BERG K, 1989, Physiotherapy Canada, V41, P304
[4]  
Chabardès S, 2002, EPILEPTIC DISORD, V4, pS83
[5]   Pharmacologic treatment of the catastrophic epilepsies [J].
Conry, JA .
EPILEPSIA, 2004, 45 :12-16
[6]   Levetiracetam in progressive myoclonic epilepsy - An exploratory study in 9 patients [J].
Crest, C ;
Dupont, S ;
Leguern, E ;
Adam, C ;
Baulac, M .
NEUROLOGY, 2004, 62 (04) :640-643
[7]   ANTIMYOCLONIC EFFECTS OF ALCOHOL IN PROGRESSIVE MYOCLONUS EPILEPSY [J].
GENTON, P ;
GUERRINI, R .
NEUROLOGY, 1990, 40 (09) :1412-1416
[8]   The history of progressive myoclonus epilepsies [J].
Genton, Pierre ;
Striano, Pasquale ;
Minassian, Berge A. .
EPILEPTIC DISORDERS, 2016, 18 :S3-S10
[9]  
Krauss JK, 2004, TIEFE HIRNSTIMULATIO
[10]   Antimyoclonic effect of levetiracetam in MERRY syndrome [J].
Mancuso, M ;
Galli, R ;
Pizzanelli, C ;
Filosto, M ;
Siciliano, G ;
Murri, L .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 243 (1-2) :97-99